IonPath's MIBI-TOF (Multiplexed Ion Beam Imaging) platform is the secret weapon here. Unlike traditional fluorescence microscopy that hits spectral overlap limits, their technology uses metal-isotope tags to simultaneously image 40+ markers on a single tissue section. This isn't incremental improvement—it's a paradigm shift that lets researchers see immune cell interactions, tumor boundaries, and biomarker expression all at once. The 'undefined' traffic share suggests they're operating in stealth mode, likely serving academic core facilities and pharma R&D teams rather than chasing mass-market adoption.

Here's the counterintuitive part: 923 monthly visits with $4.8M revenue means each visitor is worth roughly $5,200 annually. This isn't a consumer SaaS play—it's a high-velocity enterprise engine where one pharmaceutical partnership can move the needle. The 42% direct traffic is the tell: scientists are bookmarking them, coming back, and likely running pilot studies. The 33% organic search for 'mibi-tof fine resolution' suggests they're winning on technical credibility, not marketing fluff.